EE200100552A - Meetod kasvuteguri IL-5 aktiivsuse in vivo mahasurumiseks, IL-5 analoog, seda kodeeriv nukleiinhappefragment ning kasutamine immunogeense kompositsiooni valmistamiseks - Google Patents

Meetod kasvuteguri IL-5 aktiivsuse in vivo mahasurumiseks, IL-5 analoog, seda kodeeriv nukleiinhappefragment ning kasutamine immunogeense kompositsiooni valmistamiseks

Info

Publication number
EE200100552A
EE200100552A EEP200100552A EEP200100552A EE200100552A EE 200100552 A EE200100552 A EE 200100552A EE P200100552 A EEP200100552 A EE P200100552A EE P200100552 A EEP200100552 A EE P200100552A EE 200100552 A EE200100552 A EE 200100552A
Authority
EE
Estonia
Prior art keywords
analogue
vivo
activity
preparation
nucleic acid
Prior art date
Application number
EEP200100552A
Other languages
English (en)
Inventor
Klysner Steen
Original Assignee
Pharmexa A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa A/S filed Critical Pharmexa A/S
Publication of EE200100552A publication Critical patent/EE200100552A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200100552A 1999-04-23 2000-04-19 Meetod kasvuteguri IL-5 aktiivsuse in vivo mahasurumiseks, IL-5 analoog, seda kodeeriv nukleiinhappefragment ning kasutamine immunogeense kompositsiooni valmistamiseks EE200100552A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199900552 1999-04-23
US13281199P 1999-05-06 1999-05-06
PCT/DK2000/000205 WO2000065058A1 (en) 1999-04-23 2000-04-19 Method for down-regulating il5 activity

Publications (1)

Publication Number Publication Date
EE200100552A true EE200100552A (et) 2002-12-16

Family

ID=26064209

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100552A EE200100552A (et) 1999-04-23 2000-04-19 Meetod kasvuteguri IL-5 aktiivsuse in vivo mahasurumiseks, IL-5 analoog, seda kodeeriv nukleiinhappefragment ning kasutamine immunogeense kompositsiooni valmistamiseks

Country Status (19)

Country Link
US (2) US7285273B1 (et)
EP (1) EP1173573A1 (et)
JP (1) JP2002543098A (et)
KR (1) KR20020084841A (et)
CN (1) CN1355846A (et)
AU (1) AU777952B2 (et)
CA (1) CA2370391A1 (et)
CZ (1) CZ20013709A3 (et)
EA (1) EA200101125A1 (et)
EE (1) EE200100552A (et)
HR (1) HRP20010824A2 (et)
HU (1) HUP0200958A3 (et)
IL (1) IL145786A0 (et)
MX (1) MXPA01010625A (et)
NO (1) NO20015021L (et)
PL (1) PL351986A1 (et)
SK (1) SK14832001A3 (et)
TR (1) TR200103046T2 (et)
WO (1) WO2000065058A1 (et)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7097837B2 (en) 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
DE60230656D1 (de) * 2001-11-07 2009-02-12 Cytos Biotechnology Ag Antigenraster welche il-5, il-13 oder eotaxin präshilen erkrankungen
JP4533626B2 (ja) * 2001-11-07 2010-09-01 サイトス バイオテクノロジー アーゲー アレルギー性好酸球性疾患を治療するための抗原アレイ
CA2467052A1 (en) * 2001-11-16 2003-05-22 Pharmexa A/S Immunogenic mimetics of multimer proteins with promiscuous t cell epitope inserts
JP2006501249A (ja) * 2002-08-30 2006-01-12 グラクソ　グループ　リミテッド ワクチン
CA2496409A1 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
JP2007525436A (ja) * 2003-03-24 2007-09-06 マーシア・ファーマ・インコーポレイテッド 炎症症状を処置および予防するための方法および組成物
CN103091499B (zh) * 2013-01-23 2015-07-08 三峡大学 一种肿瘤标志物钙网蛋白检测试剂盒的制备及应用
SI2958937T1 (sl) * 2013-02-22 2018-12-31 Regeneron Pharmaceuticals, Inc. Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks
CA2902543A1 (en) * 2013-03-11 2014-10-09 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules
CN113214394B (zh) * 2020-10-30 2023-01-06 上海洛启生物医药技术有限公司 抗il5纳米抗体及其应用
AU2022215119A1 (en) * 2021-01-29 2023-08-17 Bayer Animal Health Gmbh Vaccine composition for breaking self-tolerance

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096704A (en) * 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
FR2677654B1 (fr) 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
AU4377793A (en) 1992-05-20 1993-12-13 Johns Hopkins University, The Alternative receptor therapy
US5616488A (en) 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. IL-5 targeted ribozymes
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
CN1135181A (zh) 1993-09-14 1996-11-06 Cytel有限公司 使用泛dr结合肽改变免疫应答
WO1995026365A1 (en) 1994-03-28 1995-10-05 United Biomedical, Inc. Synthetic peptide based immunogens for the treatment of allergy
AUPO005496A0 (en) 1996-05-24 1996-06-13 Bresagen Limited An interleukin-5 antagonist
WO1995031480A1 (en) 1994-05-18 1995-11-23 S.P.I. Synthetic Peptides Incorporated Heterodimer polypeptide immunogen carrier composition and method
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
WO1997000321A1 (en) * 1995-06-14 1997-01-03 Commonwealth Scientific And Industrial Research Organisation Immune response modulators and uses therefor
CA2745736C (en) * 1996-10-23 2016-11-22 The Trustees Of The University Of Pennsylvania Immunotherapy and improved vaccines
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
ATE359831T1 (de) 1997-01-22 2007-05-15 Zycos Inc Mikropartikel zur verabreichung von nukleinsaeuren
WO1998047923A1 (en) 1997-04-18 1998-10-29 Tanox Biosystems, Inc. Il-5r antagonists for treatment of inflammation, asthma and other allergic diseases
KR100731820B1 (ko) * 1998-10-05 2007-06-25 파멕사 에이/에스 치료적 백신화를 위한 새로운 방법

Also Published As

Publication number Publication date
IL145786A0 (en) 2002-07-25
NO20015021L (no) 2001-12-21
EP1173573A1 (en) 2002-01-23
HUP0200958A2 (en) 2002-06-29
HRP20010824A2 (en) 2002-12-31
AU4100800A (en) 2000-11-10
CZ20013709A3 (cs) 2002-11-13
JP2002543098A (ja) 2002-12-17
MXPA01010625A (es) 2003-09-04
TR200103046T2 (tr) 2002-06-21
SK14832001A3 (sk) 2003-02-04
PL351986A1 (en) 2003-07-14
US7285273B1 (en) 2007-10-23
CN1355846A (zh) 2002-06-26
US6746669B1 (en) 2004-06-08
CA2370391A1 (en) 2000-11-02
HUP0200958A3 (en) 2004-11-29
WO2000065058A1 (en) 2000-11-02
EA200101125A1 (ru) 2002-04-25
NO20015021D0 (no) 2001-10-15
AU777952B2 (en) 2004-11-04
KR20020084841A (ko) 2002-11-11

Similar Documents

Publication Publication Date Title
EE200200444A (et) Meetod autoloogse beeta-amüloidvaigu in vivo mahasurumiseks, amüloidogeense polüpeptiidi analoog, seda kodeeriv nukleiinhappefragment ning kasutamineimmunogeense kompositsiooni valmistamiseks
IL199761A0 (en) Immunogenic composition based on psoralen-inactivated hiv and method of preparing same
ZA200110161B (en) Anti-avB3 recombinant human antibodies, nucleic acids encoding same and methods of use.
ATA1292000A (de) Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
EE200300182A (et) Protsess külmkuivatatud preparaadi valmistamiseks, külmkuivatatud pantoprasooli preparaat, pantoprasooli süstelahus ja süstimiskomplekt
EG23321A (en) Artificial dermis and method of preparation.
EP1576108A4 (en) NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS OF MAKING AND USING SAME
ATE466485T1 (de) Lebensmittel enthaltend eine gelzusammensetzung sowie herstellungsverfahren
AU2002212739A1 (en) Compositions for forming bone or periodontium and injections for forming bone orperiodontium
EE04490B1 (et) Ühend, selle valmistamise meetod ning kasutamine meditsiinis
MXPA01006824A (es) Cepillo dental lingual y metodo para fabricar el mismo.
EE200100653A (et) Indolüülpiperidiinühendid, nende valmistamismeetod, kompositsioon ja nende kasutamine
AU2002231095A1 (en) Method and composition for the treatment of diabetic neuropathy
DE60126943D1 (de) Kaelteresistente fettzusammensetzung sowie verfahren zur herstellung derselben
DE60019133D1 (de) Saure proteinische lebensmittel, verfahren zur herstellung derselben sowie stabilisatoren
EP1183032A4 (en) METHOD FOR IMPROVING INSULIN EFFECT
EP1382672A4 (en) COLONY RICH IN SMALL HEPATIC CELLS, METHOD FOR OBTAINING THIS COLONY, METHOD FOR INDUCING THE MATURATION OF THIS COLONY IN HEPATIC TISSUE AND METHOD FOR ESTIMATING THE EFFECT OF A MEDICAMENT USING THIS COLONY RICH IN SMALL MATURE HEPATIC CELLS
GB2359021B (en) Method and composition for promoting hair growth
AU2001253137A1 (en) Composition and method for promoting oral health
ZA200203435B (en) Method and compositions for treating pulmonary diseases.
AU4445201A (en) Method for administering insulin to the buccal region
EP1321153A4 (en) DRUG SUBSTANCES INTENDED FOR INTERSTITIAL PNEUMONIA, METHOD OF CONSTRUCTING AN ANIMAL MODEL OF THE DISEASE, AND SCREENING METHOD USING THE SAME
HUP0201731A3 (en) Tetradeca-8,10-dienals, the method of preparation thereof and their use as sexual attractans for leafminer moths
FI990973A7 (fi) Harvesteripää ja menetelmä siinä
NO20014692D0 (no) 3-amidinobenzensulfonamidderivater, medisinske sammensetninger inneholdende slike samt intermediater vedfremstillingen derav